drugset / Trial / NCT00475800

Efficacy and Safety of Lumiracoxib in Patients With Primary Knee Osteoarthritis(OA)

NCT00475800

Phase 3 Completed 833 enrolled Novartis
Non-randomizedSingle-groupOpen-labelTreatment

Summary

This 39-week, open label study is designed to assess long-term efficacy, safety and tolerability of lumiracoxib 100mg od in patients with osteoarthritis (OA) of the knee who participated in the 13-week core CCOX189A2360 study.

Timeline

Start
2004-01
Primary completion
2004-12
Completion

Drugs

EvaluationDrugModalityDoseRoute
Subject Lumiracoxib Small molecule 100 mg

Indications